MA46860A - Inhibiteurs de magl - Google Patents

Inhibiteurs de magl

Info

Publication number
MA46860A
MA46860A MA046860A MA46860A MA46860A MA 46860 A MA46860 A MA 46860A MA 046860 A MA046860 A MA 046860A MA 46860 A MA46860 A MA 46860A MA 46860 A MA46860 A MA 46860A
Authority
MA
Morocco
Prior art keywords
magl inhibitors
magl
inhibitors
Prior art date
Application number
MA046860A
Other languages
English (en)
Inventor
Daniel J Buzard
Cheryl A Grice
Donald L Hertzog
Nicole S White
Original Assignee
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc
Publication of MA46860A publication Critical patent/MA46860A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046860A 2016-11-16 2017-11-15 Inhibiteurs de magl MA46860A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423095P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
MA46860A true MA46860A (fr) 2019-09-25

Family

ID=62107273

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046860A MA46860A (fr) 2016-11-16 2017-11-15 Inhibiteurs de magl

Country Status (27)

Country Link
US (1) US9981930B1 (fr)
EP (1) EP3541822B1 (fr)
JP (1) JP6987859B2 (fr)
KR (1) KR20190077087A (fr)
CN (1) CN110248947B (fr)
AR (1) AR110088A1 (fr)
AU (1) AU2017361250A1 (fr)
BR (1) BR112019009991A2 (fr)
CA (1) CA3043612A1 (fr)
CL (1) CL2019001335A1 (fr)
CO (1) CO2019005038A2 (fr)
CR (1) CR20190243A (fr)
DO (1) DOP2019000121A (fr)
EA (1) EA201991074A1 (fr)
EC (1) ECSP19035377A (fr)
ES (1) ES2908632T3 (fr)
IL (1) IL266550A (fr)
JO (1) JOP20190105A1 (fr)
MA (1) MA46860A (fr)
MX (1) MX2019005771A (fr)
NI (1) NI201900050A (fr)
PE (1) PE20191146A1 (fr)
PH (1) PH12019501102A1 (fr)
RU (1) RU2019116514A (fr)
TN (1) TN2019000150A1 (fr)
TW (1) TW201831458A (fr)
WO (1) WO2018093946A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2800565T (pt) 2012-01-06 2020-04-29 Scripps Research Inst Compostos de carbamato e processos para a sua preparação e utilização
KR20180004263A (ko) 2015-05-11 2018-01-10 어바이드 테라퓨틱스, 인크. 염증 또는 신경병성 통증의 치료 방법
ES2892952T3 (es) 2016-09-19 2022-02-07 H Lundbeck As Carbamatos de piperazina como moduladores del MAGL y/o ABHD6 y su uso
HUE056973T2 (hu) 2016-11-16 2022-04-28 H Lundbeck As MAGL inhibitor kristályos formája
JOP20190107A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190108B1 (ar) 2016-11-16 2023-09-17 H Lundbeck As تركيبات صيدلانية
JOP20190106A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
KR20200046061A (ko) 2017-08-29 2020-05-06 룬드벡 라 졸라 리서치 센터 인코포레이티드 스피로사이클 화합물 및 이를 제조하고 사용하는 방법
MA50524A (fr) * 2017-11-02 2020-09-09 Aicuris Gmbh & Co Kg Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb)
US10570106B2 (en) 2018-05-15 2020-02-25 Lundbeck La Jolla Research Center, Inc. MAGL inhibitors
BR112021025516A2 (pt) * 2020-04-21 2022-11-01 H Lundbeck As Processos para a fabricação de 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila e da forma 2 do sal monocloridrato do mesmo
TW202229255A (zh) 2020-11-13 2022-08-01 丹麥商H 朗德貝克公司 Magl抑制劑

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (fr) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
AU3226993A (en) 1991-11-27 1993-06-28 E.I. Du Pont De Nemours And Company Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives
JPH09506920A (ja) 1993-12-22 1997-07-08 シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー カルバメートの製造法
AU7579696A (en) 1995-11-15 1997-06-05 Zeneca Limited Herbicidal substituted pyrazole compounds
AU3440597A (en) 1996-07-02 1998-01-21 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
JP2003511362A (ja) 1999-10-04 2003-03-25 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー 新規カルバメートおよび尿素類
EP1201298A1 (fr) 2000-10-24 2002-05-02 Urea Casale S.A. Dispositif pour la condensation de carbamate
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (fr) 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Procede de preparation de carbamates
EP1716130A1 (fr) 2004-02-18 2006-11-02 AstraZeneca AB Composes acetyleniques de piperazine et leur utilisation en tant qu'antagonistes du recepteur metabotrope du glutamate
CN101018770A (zh) * 2004-04-07 2007-08-15 千禧药品公司 炎性疾病治疗用pgd2受体拮抗剂
EP1831218A2 (fr) 2004-12-23 2007-09-12 F.Hoffmann-La Roche Ag Imidazo- et pyrrolo-pyridines à substitution carbamate comme inhibiteurs de protéine kinase
ME02929B (fr) 2004-12-30 2018-04-20 Janssen Pharmaceutica Nv Dérivés d'phénylamides de 4-(benzyl)-pipérazine-1-acide carboxylique et composés similaires en tant que modulateurs de l'hydrolase des amides d'acides gras (faah) pour le traitement de l'anxiété, de la douleur et d'autres états
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎の治療方法
WO2007097470A2 (fr) 2006-02-23 2007-08-30 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné
AU2007337886C1 (en) 2006-12-22 2014-10-16 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
WO2008106047A2 (fr) 2007-02-26 2008-09-04 Kosan Biosciences Incorporated Composés de carbamate
JP2008239616A (ja) * 2007-02-28 2008-10-09 Iyaku Bunshi Sekkei Kenkyusho:Kk Hdl上昇剤
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
CA2730610A1 (fr) 2008-07-16 2010-01-21 Schering Corporation Derives heterocycliques bicycliques et leur utilisation comme modulateurs de gpcr
EP2373315A4 (fr) 2008-11-14 2012-06-27 Scripps Research Inst Procédé et composition se rapportant au ciblage de la mono-acylglycérol lipase
AU2010229134A1 (en) 2009-03-23 2011-11-10 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
IN2012DN03890A (fr) 2009-11-03 2015-09-04 Bayer Materialscience Ag
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
JP6411895B2 (ja) 2012-01-06 2018-10-24 アジオス ファーマシューティカルズ, インコーポレイテッド 治療活性化合物およびその使用方法
PT2800565T (pt) * 2012-01-06 2020-04-29 Scripps Research Inst Compostos de carbamato e processos para a sua preparação e utilização
US9567302B2 (en) 2012-03-19 2017-02-14 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
MX2015017961A (es) 2013-07-03 2016-10-14 Abide Therapeutics Inc Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos.
JP2018513119A (ja) * 2015-03-18 2018-05-24 アビデ セラピューティクス,インク. ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法
KR20180004263A (ko) * 2015-05-11 2018-01-10 어바이드 테라퓨틱스, 인크. 염증 또는 신경병성 통증의 치료 방법
WO2017143283A1 (fr) * 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Sonde de présence de monoacylglycérol lipase radiomarquée
CN109496213B (zh) * 2016-05-12 2022-03-04 H.隆德贝克有限公司 螺环化合物及其制备和使用方法
JOP20190107A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Also Published As

Publication number Publication date
MX2019005771A (es) 2019-12-05
AU2017361250A1 (en) 2019-05-30
TW201831458A (zh) 2018-09-01
RU2019116514A (ru) 2020-12-17
CR20190243A (es) 2019-06-26
US20180134675A1 (en) 2018-05-17
EP3541822B1 (fr) 2022-01-19
NI201900050A (es) 2019-10-30
CN110248947B (zh) 2022-04-01
US9981930B1 (en) 2018-05-29
JP6987859B2 (ja) 2022-01-05
JOP20190105A1 (ar) 2019-05-09
BR112019009991A2 (pt) 2019-08-27
PE20191146A1 (es) 2019-09-02
CN110248947A (zh) 2019-09-17
EP3541822A4 (fr) 2020-04-29
KR20190077087A (ko) 2019-07-02
CO2019005038A2 (es) 2019-05-31
TN2019000150A1 (en) 2020-10-05
CA3043612A1 (fr) 2018-05-24
AR110088A1 (es) 2019-02-20
IL266550A (en) 2019-07-31
DOP2019000121A (es) 2019-09-30
ES2908632T3 (es) 2022-05-03
PH12019501102A1 (en) 2019-08-19
EA201991074A1 (ru) 2019-12-30
ECSP19035377A (es) 2019-05-31
CL2019001335A1 (es) 2019-10-04
JP2020502047A (ja) 2020-01-23
EP3541822A1 (fr) 2019-09-25
WO2018093946A1 (fr) 2018-05-24

Similar Documents

Publication Publication Date Title
DK3405050T3 (da) Børnesikret snusbeholder
MA46857A (fr) Inhibiteurs de magl
DK3442972T3 (da) Bromdomænehæmmere
MA46860A (fr) Inhibiteurs de magl
MA46855A (fr) Inhibiteurs de magl
MA52635A (fr) Inhibiteurs de magl
DK3436823T3 (da) Antigen-array
DK3335532T3 (da) Tandharve
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3445708T3 (da) Stigbøjle
DK3402792T3 (da) Quinolin-2-on-derivater
DK3509963T3 (da) Pallecontainer
MA50406A (fr) Inhibiteurs pyrazole de magl
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
DK3575238T3 (da) Pallecontainer
DE112017006386A5 (de) Schraubarbeitszylinder
MA46889A (fr) Inhibiteurs de gsk-3
DK3323708T3 (da) Bovfender
DK3481826T3 (da) Tyrosinkinaseinhibitorer
DK3471535T3 (da) Dyrelift
MA46888A (fr) Inhibiteurs de gsk-3
DK3452590T3 (da) Plademagnet
DK3452587T3 (da) Penicillin-g-acylaser
DK3430609T3 (da) Smartflag